Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmeriHealth Formulary Coverage & Prior Auth Policy…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAmeriHealthPolicy N/A

    AmeriHealth Value Formulary Guide — Coverage & Prior Authorization Criteria

    Customize your policy alerts

    Sign up for all AmeriHealth policy alerts

    Know when AmeriHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Explains the AmeriHealth Value formulary design, tier structure, safety procedures (prior authorization, quantity and age limits, MME and stimulant limits), and member/provider responsibilities for prescription drug coverage. Affects AmeriHealth members and their prescribing providers.

    Policy Summary
    PayerAmeriHealth
    PolicyAmeriHealth Value Formulary Guide — Coverage & Prior Authorization Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization with complete clinical information for drugs flagged PA or when utilization thresholds (e.g., >90 MME/day, stimulant cumulative limits, high-cost claims) are exceeded.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    90opioid MME PA threshold
    60amphetamine-class high dose
    72methylphenidate high dose
    10kclaim dollar review threshold
    75compound cost PA threshold
    75%refill-too-soon rule

    Coverage Criteria and Triggers

    Opioid MME Authorization Criteria

    Prior authorization required when ANY of the following dosing thresholds are exceeded

    Opioid MME threshold: Total daily opioid dose exceeds 90 MME (across opioid products)>90 MME/day

    Includes all monitored opioid active ingredients listed in policy

    Cumulative Stimulant Authorization Criteria

    Prior authorization required when stimulant cumulative doses exceed ingredient-specific thresholds

    Amphetamine-class high dose: Amphetamine, amphetamine-dextroamphetamine, dextroamphetamine, methamphetamine exceed 60 mg/day>60 mg/day

    Specific impacted medications listed in policy (brands and generics)

    Policy Summary
    PayerAmeriHealth
    PolicyAmeriHealth Value Formulary Guide — Coverage & Prior Authorization Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization with complete clinical information for drugs flagged PA or when utilization thresholds (e.g., >90 MME/day, stimulant cumulative limits, high-cost claims) are exceeded.
    SourceLink
    On This Page
    Coverage Criteria and TriggersFormulary Codes, Flags, and Key ThresholdsProvider Responsibilities, Prior Authorization and DocumentationFormulary Background and ScopeKey Terms and AbbreviationsStep Therapy and Trial RequirementsQuantity, Supply, and Refill Limits
    Dexmethylphenidate high dose: Dexmethylphenidate exceeds 40 mg/day>40 mg/day

    Impacted medications listed (e.g., Focalin IR/XR)

    Methylphenidate high dose: Methylphenidate exceeds 72 mg/day>72 mg/day

    Impacted medications listed (e.g., Ritalin, Concerta, Daytrana, Quillivant, Jornay PM, others)

    Serdexmethylphenidate high dose: Serdexmethylphenidate (Azstarys) exceeds 52.3 mg/day>52.3 mg/day

    Impacted medication listed: Azstarys

    Cost-based Authorization Criteria

    Prior authorization or additional review required for high-cost or high-cost-per-prescription products

    Compound cost threshold: Compound products with total cost >= $75 per prescription require prior authorization or review>= $75 per prescription
    High dollar claim threshold: Prescription claims exceeding $10,000 per claim require review or authorization> $10,000 per claim

    Inclusion of a medication on the AmeriHealth Value formulary does not automatically guarantee coverage for all member benefit plans. Non‑formulary (NF) drugs are only covered when a formulary exception or prior authorization is obtained, and when approved the member may be responsible for the highest non‑specialty level of cost‑sharing. See the Procedures that Support Safe Prescribing for details on exception processing and plan‑specific benefit availability.

    Tier‑exception requests are subject to specific limits. Providers may request exceptions when criteria are met (for example, documented trials or contraindications to formulary alternatives), but tier exceptions are not available for drugs placed on the generic, preferred brand, or specialty tiers. Individual plan benefit designs may further restrict availability of tier exceptions; refer to the member benefit booklet for plan‑level rules.

    The excerpts in this section do not specify discrete clinical exclusions framed as medical necessity rules; instead the guidance and product listings use tier and administrative annotations (for example, PA, QL, AL, SP, NF) to communicate utilization controls and coverage requirements.

    Several entries in the formulary excerpt are marked NF (Non‑Formulary). Examples shown in the list include topical and cardiovascular products such as Rectiv and other items flagged as NF in the drug table. NF designation indicates those products are not on the preferred coverage tiers in the sample excerpt.

    The provided excerpt does not contain formal, standalone medical‑necessity exclusion statements. Coverage direction is communicated through formulary tiering and utilization flags (e.g., PA, QL, AL, NF) applied at the drug line level rather than separate exclusion text.

    Drugs labeled NF (Non‑Formulary) are designated non‑formulary in the formulary listing. An NF designation means coverage is limited or may be denied unless a formulary exception or prior authorization is obtained in accordance with the exception and PA processes described in the formulary documentation.

    Formulary Codes, Flags, and Key Thresholds

    Formulary flags and tier codesmixed
    PAPrior Authorization (legend)
    QLQuantity Limits Apply (legend)
    QITQuantity Over Time (legend)
    SPSpecialty Drug (legend)
    ALAge Limit (legend)
    LCGLow Cost Generic (legend)
    GGeneric tier
    NFNon-Formulary tier
    PBPreferred Brand tier
    NPDNon-Preferred Drug
    Formulary entries (no CPT/HCPCS/NDC codes present in this excerpt)mixed
    No codes listed
    Opioid MME limit
    Opioid MME threshold> 90 MME per day requires prior authorization
    ScopeApplies to total daily opioid dose across monitored opioid active ingredients (MME calculated across products)
    ActionPrior authorization required when total daily opioid dose exceeds 90 MME
    Opioid MME limit (duplicate)
    Opioid MME threshold (duplicate)> 90 MME/day requires prior authorization
    Denial riskOpioid prescriptions exceeding 90 MME/day may be denied without prior authorization
    CalculationMME is calculated based on opioid potencies and total daily usage across products
    Amphetamine high cumulative dose
    Amphetamine-class high cumulative dose60 mg/day prior authorization threshold
    Affected agentsIncludes amphetamine, amphetamine-dextroamphetamine, dextroamphetamine, methamphetamine (brands/generics listed in policy)
    Provider actionClaims exceeding the cumulative 60 mg/day threshold require prior authorization
    Dexmethylphenidate high cumulative dose
    Dexmethylphenidate threshold40 mg/day prior authorization threshold
    Example productFocalin (IR/XR) and generics referenced in policy
    RequirementClaims exceeding 40 mg/day require prior authorization
    Methylphenidate high cumulative dose
    Methylphenidate threshold72 mg/day prior authorization threshold
    Affected productsIncludes Ritalin (IR/LA), Concerta, Daytrana, Aptensio XR, Quillivant XR, Jornay PM, and others listed
    ActionPrior authorization required when cumulative methylphenidate exceeds 72 mg/day
    Serdexmethylphenidate high cumulative dose
    Serdexmethylphenidate threshold52.3 mg/day prior authorization threshold
    Example productAzstarys (serdexmethylphenidate) referenced in policy
    RequirementClaims exceeding 52.3 mg/day require prior authorization
    Age Limit and Quantity Over Time indicators
    Age Limit (AL) presentSome products on the formulary are annotated with AL to indicate coverage may be restricted by member age
    Quantity Over Time (QIT) presentSelected products include QIT annotations (quantity limits based on rolling time windows)
    Where shownAL and QIT flags appear in the REQUIREMENTS/LIMITS column for specified products (see drug rows)
    Morphine Milligram Equivalent (MME)
    MME definition/roleMorphine Milligram Equivalent (MME) is used to compare opioid potency and determine total daily opioid exposure for safety and prior authorization thresholds
    Use in utilization controlsMME calculations are applied as a utilization control where indicated (e.g., MME limit triggers PA)
    Calculation noteDaily MME is calculated across opioid products considering potency and total daily usage

    Provider Responsibilities, Prior Authorization and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for certain covered drugs. Providers must obtain approval from AmeriHealth (via the PBM) to confirm medical necessity and appropriateness before the prescription will be covered at retail or mail-order pharmacies. The authorization review may take up to two business days once complete information is received; incomplete submissions may delay decisions. Some approvals are time‑limited (e.g., 6–12 months) and require reauthorization after expiration.

    • Claims exceeding the claim dollar threshold ($10,000) require prior review and the provider must submit a PA request.
    • Compound products with total cost ≥ $75 per prescription require review/authorization.
    • Certain drugs additionally require a benefit rider (e.g., some weight‑loss drugs) — verify member eligibility with the health plan.
    Prior Authorization

    Drug‑specific Prior Authorization List

    A long list of specific drugs and product families require prior authorization. This applies to all formulations (tablet, capsule, suspension, injectables, specialty presentations) when the formulary row shows REQUIREMENTS/LIMITS = PA.

    • Examples (not exhaustive): abiraterone, adalimumab products, apomorphine inj, Alyftrek, brivaracetam, Cabometyx, Calquence, Dupixent, Emgality, Ibrance, Imbruvica, Liraglutide, Mounjaro, Ozempic, Skyrizi, Spevigo, many oncology, dermatology, and specialty agents.
    • All brand prenatal vitamins require authorization.
    • Providers must submit PA requests with complete clinical information for listed products to the PBM (ePA portal, fax to 1‑888‑671‑5285, or PBM portal).
    Prior Authorization

    Prior Authorization for Select Agents

    Select agents and specialty products listed in the formulary carry a PA flag and may also have additional limits (QL, QIT, SP, LDD, SDS). Prior authorization is required at claim processing for these products; failure to obtain PA may result in denial.

    • Specialty (SP) drugs often require PA and may be subject to limited distribution (LDD) or supply limits (SDS).
    • Formulary entries show combined flags (e.g., PA, QL, QIT) — review the REQUIREMENTS/LIMITS column for each drug.
    Prior Authorization

    Prior Authorization Applies to Listed Drugs

    Prior authorization applies to many drugs listed in the formulary where REQUIREMENTS/LIMITS is annotated with PA. Claims for these drugs will require PA at point of dispensing and may be rejected if authorization is not on file.

    • Coverage status and PA requirements are shown per‑drug in the formulary rows; check DRUG TIER and REQUIREMENTS/LIMITS before dispensing.
    • Examples include oncology and immunology agents (numerous entries show PA and SP).
    Denial Risk

    Denial Risk Without Prior Authorization

    Failure to obtain required prior authorization, or exceeding limits (MME, QL, QIT, claim dollar limits), may result in claim denial. Providers and members will be notified if a request is denied and appeals information will be included in the denial communication.

    • Denial triggers include: missing PA, exceeding quantity limits (QL/QIT), supply limits (SDS), limited distribution constraints (LDD), non‑formulary (NF) exclusions, and claim dollar thresholds.
    • If denied, the prescribing provider and member receive notification and appeals instructions.
    Denial Risk

    MME Limit — Prior Authorization for >90 MME/day

    AmeriHealth enforces a Morphine Milligram Equivalent (MME) daily limit for opioid safety. Prior authorization is required for opioid regimens that exceed 90 MME/day. Claims above the MME threshold may be denied without an approved PA.

    • MME applies across opioid products and is calculated using each product's potency and total daily usage.
    • Affected active ingredients include morphine, hydromorphone, fentanyl, hydrocodone, oxycodone, oxymorphone, tapentadol, tramadol, methadone, and others listed in the formulary.
    • Some opioid products in the formulary are flagged with MME and PA in the REQUIREMENTS/LIMITS column.
    Denial Risk

    Cumulative Stimulant Limit — PA Required for High Doses

    A cumulative stimulant dose limit is enforced by active ingredient. Stimulant claims that exceed the defined ingredient‑specific daily thresholds require prior authorization and may be denied without approval.

    • Example high cumulative daily thresholds: amphetamine family = 60 mg/day; dextroamphetamine = 60 mg/day; dexmethylphenidate = 40 mg/day; methylphenidate = 72 mg/day; lisdexamfetamine and others as defined in the formulary.
    • Providers should review total daily stimulant dose across all products with the same active ingredient before prescribing/dispensing.
    Prior Authorization

    Prior Authorization Triggers on the Formulary

    Prior authorization is triggered at claim processing when the formulary 'REQUIREMENTS/LIMITS' field contains flags such as PA, QL (quantity limits), QIT (quantity over time), SP (specialty), AL (age limit), LDD (limited distribution), SDS (supply limit), NF (non‑formulary), or MME. Claims with these flags will be subject to the corresponding review and may require submission of clinical documentation.

    • Check the formulary row for each drug to determine which flags apply before submitting or dispensing.
    • PA triggers include product‑specific entries and class‑level safety edits (e.g., MME, stimulant cumulative limits).
    Documentation Required

    Required Documentation When Controls Apply

    When controls such as PA, QL, MME, SDS, or LDD apply, providers must submit required clinical documentation with the PA request. Lack of documentation can delay review or result in denial.

    • Required documentation may include medical history, prior therapy trials, dosing rationale, lab results, and letters of medical necessity.
    • Supply limits (SDS) and limited distribution (LDD) requirements may affect where and how the drug is obtained — include distribution details when relevant.
    Note

    Formulary Legend and Required Codes

    The formulary legend defines the meaning of codes/flags used in the REQUIREMENTS/LIMITS column. Providers must understand these abbreviations when evaluating coverage and submission requirements.

    • PA = Prior Authorization; QL = Quantity Limits Apply; QIT = Quantity Over Time; SP = Specialty Drug; AL = Age Limit.
    • LDD = Limited Distribution Drug; SDS = Supply Limit; R = Requires Rider; NF = Non‑Formulary; PB = Preferred Brand; NPD = Non‑Preferred.
    • MME = Morphine Milligram Equivalent; Claim Dollar Limit refers to per‑claim dollar review thresholds.
    Step Therapy

    Formulary Exceptions and Step‑Therapy Notes

    Formulary exceptions and step‑therapy requests are handled via specific exception forms. Providers may request coverage of non‑formulary or tier exceptions, typically requiring documentation of trials of and/or contraindications to formulary alternatives. Some plans do not permit tier exceptions; review the member's benefit booklet.

    • Formulary exception for non‑formulary drugs generally requires trial of (or contraindication to) at least three formulary alternatives when applicable.
    • Tier exceptions for generic, preferred brand, or specialty tiers are subject to plan rules and may be unavailable for some tiers.
    • Submit formulary exception requests using the exception form and fax to 1‑888‑671‑5285; approved exceptions will adjust the member's cost‑sharing level accordingly.
    Step Therapy

    Step Therapy — Details Managed by PBM

    The formulary excerpts do not provide detailed step‑therapy sequences. While some entries imply prior steps or alternatives via tiering and PA requirements, specific step‑therapy algorithms are managed by the PBM and must be confirmed with the PBM's criteria.

    • Where step therapy is required, the PBM maintains the clinical criteria and step sequence — providers should consult the PBM ePA portal or criteria documents.
    • Do not assume step order from tiering or PA flags alone; submit clinical rationale and prior therapy history when requesting PA or exceptions.

    Formulary Background and Scope

    Background: The AmeriHealth Value formulary is selected to promote safety, effectiveness, and value. Formulary decisions and utilization management procedures are guided by the local Pharmacy & Therapeutics Committee and implemented by the pharmacy benefits manager. Safety edits described in the formulary (for example, prior authorization, quantity limits, age limits, MME and stimulant dose limits) are applied to support appropriate prescribing and member safety; providers must follow the documented PA and exception procedures when requesting coverage outside standard formulary placement.

    Key Terms and Abbreviations

    Formulary
    Formulary definitionA list of prescribed medications or other pharmacy care products, services or supplies chosen for safety, cost, and effectiveness; medications are listed by category and placed into tiers
    GovernanceList is guided by a Pharmacy & Therapeutics Committee which reviews coverage, effectiveness, and value
    IncludesBoth brand and generic prescription medications are included and placed into tiers
    Tiers
    Formulary tiersLow-Cost Generic; Generic; Preferred Brand; Non-preferred Drug; Non-Formulary; Specialty
    MeaningTiers reflect cost-sharing levels; non-preferred and non-formulary tiers generally have higher cost-sharing and may require exceptions for coverage
    AvailabilityNot all tiers or incentives (e.g., LCG) are available on all plans
    Morphine Milligram Equivalent (MME) definition
    MME definitionMorphine Milligram Equivalent is a calculated value used to compare opioid potency and determine total daily opioid exposure
    PurposeUsed to identify when additional caution or utilization controls (e.g., prior authorization) are needed
    ApplicationMME-based limits are applied to opioid prescribing and claims adjudication
    Concurrent Drug Utilization Review (cDUR)
    cDUR definitionConcurrent Drug Utilization Review (cDUR) are automated pharmacy claim reviews at point-of-sale for safety concerns such as drug-drug interactions and therapy duplications
    FunctionMay generate rejects or pharmacist alerts at POS; pharmacist can review and override when appropriate
    ExamplesDrug-drug interaction alerts (e.g., sildenafil + nitroglycerin) and therapy duplication alerts (e.g., multiple statins)
    PA definition
    PA definitionPA = Prior Authorization — requires approval from the health plan before coverage/dispensing
    Usage in formularyPA is shown in the REQUIREMENTS/LIMITS field for drugs that require prior approval
    Provider actionProviders must submit PA requests per payer process to obtain coverage for PA‑designated drugs
    QL definition
    QL definitionQL = Quantity Limits Apply — the product has limits on the amount covered over time
    TypesIncludes maximum daily dose, quantity over time (QIT), and supply limits (SDS) as applicable
    DocumentationSupporting documentation may be required to justify quantities above limits
    QIT definition
    QIT definitionQIT = Quantity Over Time — a quantity limit based on dosing over a rolling time period (e.g., 30-day lookback)
    PurposePrevents dispensing excessive quantities by counting prior fills over the defined time window
    ExamplesNuvaring = 1 per 28 ring days; other drugs annotated with QIT in the formulary list
    SP definition
    SP definitionSP = Specialty Drug — drugs meeting criteria such as treatment of rare/complex conditions, complex storage/shipping, or requiring intensive monitoring
    ManagementSpecialty drugs may be managed by a Specialty Pharmacy Program and placed on a specialty tier with higher cost-sharing
    ImplicationSP designation may require specialty distribution, PA, or LDD handling
    AL definition
    AL definitionAL = Age Limit — coverage may be restricted based on member age for annotated products
    UsageAge limits are shown in the REQUIREMENTS/LIMITS column for specific dermatologic and other products
    ExamplesRetin-A and certain topical products include AL annotations in the formulary list
    LCG definition
    LCG definitionLCG = Low-Cost Generic — a tier offering lower copays than the standard generic tier for selected chronic-use generics (availability varies by plan)
    Plan variabilityNot all plans provide LCG; when not available, drugs are covered at the generic cost-share level
    PurposeIntended to provide lower member cost-share for commonly used chronic medications
    PA (legend)
    PA (legend repetition)PA = Prior Authorization
    ContextShown in formulary legend and used in REQUIREMENTS/LIMITS column
    Action impliedPA designation requires submission of prior authorization to obtain coverage
    QL (legend)
    QL (legend repetition)QL = Quantity Limits Apply
    ContextAppears in the formulary legend and drug rows to indicate quantity restrictions
    DocumentationProviders may need to provide supporting documentation to exceed QL
    QIT (legend)
    QIT (legend repetition)QIT = Quantity Over Time
    ContextUsed in legend and product rows to indicate rolling lookback quantity limits
    Relation to QLQIT is a form of quantity limit applied over a defined time window
    SP (legend)
    SP (legend repetition)SP = Specialty Drug
    ContextIndicates specialty tier designation in the formulary legend
    ImplicationSP flag may indicate specialty distribution, PA, or higher cost-sharing
    Utilization flags and tier abbreviations
    Consolidated legendPA = Prior Authorization; QL = Quantity Limits Apply; QIT = Quantity Over Time; SP = Specialty Drug; AL = Age Limit; LDD = Limited Distribution Drug; SDS = Supply Limit; NF = Non Formulary; PB = Preferred Brand; NPD = Non Preferred; G = Generic; LCG = Low Cost Generic
    Where usedLegend appears at top of drug list and guides interpretation of REQUIREMENTS/LIMITS entries
    EffectThese abbreviations trigger specific provider actions (e.g., PA requires submission of prior authorization)
    MME (legend reference)
    MME (legend reference)MME = Morphine Milligram Equivalent — referenced as a utilization control for opioid medications
    FunctionUsed to impose opioid daily dose limits that trigger PA and other safety edits
    PlacementMME appears in the legend and in multiple drug rows where opioid controls apply
    PA (duplicate)
    PA (definition duplicate)Prior Authorization — requires approval before coverage
    NoteRepeated across legend sections to emphasize PA requirement
    Provider implicationClaims for PA-designated drugs may be denied without authorization
    QL (duplicate)
    QL (definition duplicate)Quantity Limits Apply — product has limits on amount covered over time
    ExamplesMaximum daily dose, QIT, and SDS are types of QL shown in drug rows
    Provider implicationExceeding QL may require PA or supporting documentation
    SDS (Supply Limit) definition
    SDS definitionSDS = Supply Limit — limits based on supply (e.g., days' supply) apply to some drug classes such as opioids
    ExampleShort-acting opioids have supply limits expressed as two 5‑day supplies per 60 days for adults (see QL examples)
    ImplicationSDS may be shown with QL and MME in REQUIREMENTS/LIMITS for certain products
    NF / NPD / PB / G / LCG
    Tier abbreviationsNF = Non-Formulary; NPD = Non-Preferred Drug; PB = Preferred Brand; G = Generic; LCG = Low Cost Generic
    MeaningThese abbreviations indicate the formulary tier and corresponding cost-share level for listed products
    UsageShown in drug rows to indicate tier placement
    PA (additional legend)
    PA (additional legend)PA = Prior Authorization (requires approval prior to coverage)
    ContextRepeated in multiple legend blocks for clarity
    Provider actionSubmission of PA per payer process is required for coverage of PA‑flagged drugs
    QL (additional legend)
    QL (additional legend)QL = Quantity Limits Apply — product has limits on amount covered over time
    Provider implicationQL annotations may require documentation to justify quantities above limits
    ExamplesMaximum daily dose and supply limits shown in the formulary list
    SP (additional legend)
    SP (additional legend)SP = Specialty Drug — drugs requiring specialized handling, monitoring, or distribution
    ImplicationSP designation may be associated with PA, QL, LDD, or specialty pharmacy management
    Where shownAppears in the legend and in individual drug rows for specialty products
    LDD definition
    LDD definitionLDD = Limited Distribution Drug — drugs distributed through limited channels and may require specific handling
    ImplicationClaims for LDD products may require coordination with specialty distribution and PA
    UsageShown in formulary rows for selected specialty products
    NF definition
    NF definitionNF = Non-Formulary — product is non‑formulary and may require a formulary exception for coverage
    Coverage implicationNon‑formulary drugs are covered only when a formulary exception/PA is obtained and may carry higher cost-sharing
    Where shownNF appears in the REQUIREMENTS/LIMITS and tier columns throughout the drug list
    NPD definition
    NPD definitionNPD = Non-Preferred Drug — a tier that usually has higher cost-sharing than preferred brand or generic tiers
    EffectMay be associated with PA or QL depending on the product
    PlacementUsed in the tier column for many listed products
    G definition
    G definitionG = Generic — generic tier placement for medications
    Cost-shareGeneric tier typically has lower cost-sharing than brand tiers
    UsageShown in tier column for generic products in the formulary list
    PB definition
    PB definitionPB = Preferred Brand — brand-name drugs with preferred status on the formulary
    Cost-sharePreferred Brand tier generally has lower cost-sharing than Non-Preferred Drug or Non-Formulary tiers
    UsageAppears in tier column for selected brand products
    AL definition (duplicate)
    AL (duplicate)AL = Age Limit — coverage may be restricted by member age
    ExamplesMultiple topical agents and other products include AL annotations in drug rows
    Provider actionCheck AL annotation on drug row when prescribing to verify age-based coverage limits
    Formulary annotation definitions
    Formulary annotation definitionsLegend abbreviations define utilization controls and tier codes used across the formulary (PA, QL, QIT, SP, AL, LDD, SDS, NF, PB, NPD, G, LCG)
    PurposeHelps providers interpret REQUIREMENTS/LIMITS annotations on each drug row
    ReferenceLegend appears in multiple chunks and should be consulted when submitting claims or PA requests
    PA definition (alternate)
    PA (alternate chunk)PA = Prior Authorization — requires approval prior to dispensing/coverage
    NotationRepeated across legend blocks for clarity
    ImplicationClaims for PA-designated drugs are at risk for denial without authorization
    QL definition (alternate)
    QL (alternate chunk)QL = Quantity Limits Apply — indicates quantity restrictions on coverage
    ExamplesMaximum daily dose and supply limits shown in QL examples
    Provider implicationSupporting documentation may be required to exceed QL
    AL definition (alternate)
    AL (alternate chunk)AL = Age Limit — indicates coverage may be restricted by age for specific products
    ExamplesTopical dermatologic agents frequently include AL annotations
    Provider actionVerify patient age against AL annotation before dispensing or submitting PA
    SP definition (alternate)
    SP (alternate chunk)SP = Specialty Drug — drugs meeting criteria for specialty handling and monitoring
    ManagementMay be managed by a Specialty Pharmacy Program and have higher cost-sharing
    AnnotationsSP appears in legend and in drug rows to indicate specialty status
    NF definition (alternate)
    NF (alternate chunk)NF = Non-Formulary — product is non‑formulary and may require a formulary exception for coverage
    Coverage implicationNon‑formulary status often results in restricted coverage unless exception/PA is approved
    Where usedAppears throughout the formulary tier column and drug rows
    PB definition (alternate)
    PB (alternate chunk)PB = Preferred Brand — brand-name drugs with preferred formulary placement
    Cost-sharingPreferred Brand tier has cost-sharing characteristics distinct from NPD and NF tiers
    UsageAppears in tier column for selected brand products
    NPD definition (alternate)
    NPD (alternate chunk)NPD = Non-Preferred Drug — tier indicating non-preferred status with higher cost-sharing
    AnnotationUsed in drug rows to indicate tier placement and possible PA/QL requirements
    ImplicationMay influence step/PA requirements per plan rules
    PA (short)
    PA (short legend)PA = Prior Authorization
    ContextShort legend repeats PA meaning for quick reference
    EffectPA flag requires prior approval for coverage
    QL (short)
    QL (short legend)QL = Quantity Limits Apply
    ContextShort legend repeats QL meaning for quick reference
    EffectIndicates quantity restrictions on coverage
    SP (short)
    SP (short legend)SP = Specialty Drug
    ContextShort legend repeats SP meaning for quick reference
    ImplicationSP flag may indicate specialty pharmacy handling and higher cost-share
    NF (short)
    NF (short legend)NF = Non‑Formulary
    ContextShort legend repeats NF meaning for quick reference
    Coverage implicationNF items may require exception/PA for coverage
    PB (short)
    PB (short legend)PB = Preferred Brand
    ContextShort legend repeats PB meaning for quick reference
    UsageIndicates preferred brand placement in formulary tiers
    NPD (short)
    NPD (short legend)NPD = Non‑Preferred
    ContextShort legend repeats NPD meaning for quick reference
    ImplicationNon‑preferred status may affect cost-sharing and utilization management
    LDD (short)
    LDD (short)LDD = Limited Distribution Drug
    ContextIndicates limited distribution handling for select products
    ImplicationMay require coordination with specialty distributors and PA
    Formulary abbreviations
    Formulary abbreviations (legend)Common abbreviations used across the formulary: PA, QL, QIT, SP, AL, LDD, SDS, NF, PB, NPD, G, LCG
    PurposeHelps interpret requirement/limit annotations in drug list
    ReferenceLegend appears in multiple locations in the document
    PA (repeat)
    PA (definition repeat)Prior Authorization — approval required prior to coverage/dispensing
    ImplicationClaims without PA where PA is required are at risk of denial
    Provider actionSubmit PA per payer instructions to avoid denial
    QL (repeat)
    QL (definition repeat)Quantity Limits Apply — product has amount limits over a time period
    Provider implicationExceeding QL may require PA or documentation
    ExamplesMaximum daily dose and rolling QIT examples provided in document
    SP (repeat)
    SP (definition repeat)Specialty Drug — drug requiring specialized handling/monitoring
    ImplicationMay be managed through Specialty Pharmacy Program with PA/QL/LDD requirements
    Where shownSP flags appear in drug rows and legend
    NF (repeat)
    NF (definition repeat)Non-Formulary — product not on formulary; coverage typically requires exception/PA
    Coverage implicationNF designation may result in denial without approved exception
    ReferenceUsed widely in tier column across drug list

    Step Therapy and Trial Requirements

    RequirementNotes
    Providers must document trials of, or contraindications to, formulary alternatives when requesting coverage of a non‑formulary medicationWhen requesting a formulary exception, providers should complete the exception request form and fax to 1-888-671-5285 with supporting clinical detail; tier exceptions are not available for drugs on the generic, preferred brand, or specialty tiers
    Formulary exception requests for non‑formulary drugs require documentation that at least three formulary alternatives were tried or shown to be contraindicated when applicableIf an exception is approved the drug will be covered at the appropriate preferred brand or generic level; denials will be communicated with appeals language
    ObservationSource implication
    No explicit step‑therapy sequences are listed in the provided formulary excerptThe formulary rows show utilization flags (e.g., PA, QL, QIT, SP) but do not define required step‑by‑step therapy sequences
    Coverage controls appear as per‑drug attributes (PA, QL, QIT, AL, SP) rather than as explicit multi‑step algorithms in this excerptStep therapy specifics are managed by the PBM and are not detailed in these chunks
    ObservationImplication for providers
    Several non‑preferred or specialty drugs are annotated with 'PA' in the requirements/limits field (examples shown across the list)These annotations indicate prior authorization is required; explicit step rules or exact prior‑trial requirements are not provided in this fragment
    Providers should expect to submit PA requests for non‑preferred or specialty agents marked 'PA' and provide supporting clinical documentation per PA processIf step edits are implemented by the PBM they will be applied per plan/PBM rules; not specified here
    ObservationImplication
    Multiple specialty or non‑preferred agents are marked with tier codes (NPD, PB, SP) and have 'PA' in their REQUIREMENTS/LIMITS fieldExamples in the list include agents where PA is required alongside specialty designation
    Such agents will require prior authorization before coverage and may be subject to PBM step edits per plan rules, though specific step sequences are not listed hereProviders should consult plan/PBM procedures when submitting PA for specialty or non‑preferred medications
    ObservationPractice note
    Some topical agents are designated as Non‑Preferred (NPD) or Non‑Formulary (NF) in the list; several topical entries also show 'AL' or 'PA' flagsExamples include adapalene formulations with AL and PA annotations in the excerpt
    NPD/NF designation and PA or AL flags imply that prior authorization, age limits, or formulary exception processes may apply per plan rulesSpecific step therapy edits for topical agents are not defined in this excerpt; providers should follow PA and exception procedures as indicated
    ObservationSummary
    The excerpt does not provide explicit step‑therapy sequences; individual drug rows primarily show PA and QL flagsDexcom sensors and many insulin/diabetes supplies are annotated with PA and QL but no step order is shown
    Providers should prepare to submit PA or document need for quantity overrides when PA/QL flags are present; step‑by‑step algorithms are not specified hereRefer to PBM/plan procedures for any step therapy requirements that may exist outside this excerpt
    ObservationImplication
    Some devices and diabetic meters/supplies (e.g., Omnipod systems, Dexcom sensors, test strips, glucometers) are annotated with PA and/or QL in the listExamples include Omnipod entries and Dexcom Continuous Glucose Monitor sensors showing PA and QL
    Coverage for these devices/supplies may require prior authorization and are subject to quantity limits; the excerpt does not define any step‑therapy ordering for device coverageProviders should follow PA submission and quantity‑limit documentation procedures for diabetes devices per plan/PBM guidance
    ObservationNote
    The fragment does not specify any step‑therapy sequences; it shows formulary abbreviations and per‑product flags (PA, QL, SP, AL, NF, NPD) onlyTestosterone products and other listed items are shown with tier and requirement flags but no step edit instructions
    Where PA/QL flags appear, prior authorization or quantity limits may be enforced; step therapy applicability (if any) should be confirmed with the PBM/planProviders should ensure required documentation accompanies PA requests to avoid denial

    Quantity, Supply, and Refill Limits

    Refill rule
    Refill ruleMember may refill after 75% of previous supply has been used (refill-too-soon limit)
    ExamplesA 30‑day supply filled on 1/1/2025 is refillable on or after 1/24/2025; a 90‑day supply filled 7/1/2025 is refillable on or after 9/7/2025
    PurposeTo encourage appropriate utilization and minimize stockpiling
    Short-acting opioids example limit
    Short-acting opioid supply limit (adults)Two 5-day supplies per 60 days without authorization
    Short-acting opioid supply limit (children <18)Two 3-day supplies per 60 days without authorization
    Maximum quantity without authorization30 tablets (example: oxycodone/acetaminophen 5/325 mg) — max quantity without authorization
    Ibandronate (Boniva 150 mg)
    Ibandronate (Boniva 150 mg)1 tablet per 30 days (quantity limit)
    ReferenceExample listed under Quantity Over Time in document
    ImplicationQL annotation enforces monthly limit for this product
    Sumatriptan (Imitrex)
    Sumatriptan (Imitrex)18 tablets per 30 days (quantity limit)
    ContextListed as an example of Quantity Over Time limits
    Provider implicationDispensing beyond this limit may require PA or documentation
    Sildenafil, Tadalafil
    Sildenafil / Tadalafil8 tablets per 30 days (quantity limit)
    ContextExample provided in Quantity Over Time section
    ImplicationQL annotation limits monthly quantity for erectile dysfunction agents
    Zolpidem (Ambien)
    Zolpidem (Ambien)1 tablet per day maximum (maximum daily dose)
    ContextProvided as an example of maximum daily dose QL
    Provider implicationDispensing beyond daily limit may require PA or documentation
    Butalbital-containing headache agents
    Butalbital-containing agentsQuantity limit = 6 tablets per day; supply limit = 5-day supply per 30 days; maximum without authorization = 30 tablets
    Example agentsButalbital/aspirin and similar headache combinations
    ImplicationExceeding these QL/SDS values may require prior authorization
    Opioid-containing cough/cold products
    Opioid-containing cough/cold productsQuantity limit = 30 mL per day; supply limit = two 5-day supplies per 60 days for adults (two 3-day supplies for children <18); maximum without authorization = 150 mL
    Example agentsHydrocodone/homatropine and similar cough/cold opioid formulations
    ImplicationSDS and QL annotations enforce these limits; PA may be required for larger quantities
    Cresemba — QL and QIT noted
    CresembaAnnotated with PA, QL, QIT in formulary list
    ImplicationClaims for Cresemba require prior authorization and are subject to quantity limits and quantity-over-time rules
    ReferenceSee REQUIREMENTS/LIMITS column in drug row
    Itraconazole; ivermectin; griseofulvin
    Itraconazole, Ivermectin, GriseofulvinFormulary rows include QIT or QL flags for specific formulations (exact numeric quantities not listed)
    ImplicationQuantity-over-time or quantity limits apply to specified formulations as indicated in the drug rows
    ReferenceSee drug rows with REQUIREMENTS/LIMITS annotations for details
    Molnupiravir 200mg
    Molnupiravir 200 mgAnnotated with QL and AL in formulary list
    ImplicationQuantity limits and age limits apply to this product as noted in drug row
    ReferenceSee REQUIREMENTS/LIMITS column for Molnupiravir 200 mg
    Sofosbuvir-velpatasvir 400-100mg
    Sofosbuvir-velpatasvir 400/100 mgAnnotated with QL (and PA in some rows) in formulary list
    ImplicationQuantity limits apply; prior authorization may also be indicated depending on row
    ReferenceSee REQUIREMENTS/LIMITS column for specifics
    Solodyn
    SolodynAnnotated with QL and QT in formulary list
    ImplicationQuantity limits and quantity-over-time rules apply to Solodyn formulations
    ReferenceSee drug row REQUIREMENTS/LIMITS for details
    Imbruvica
    ImbruvicaAnnotated with QL in formulary list
    ImplicationQuantity limits apply to Imbruvica as shown in drug row
    ReferenceSee REQUIREMENTS/LIMITS in the formulary listing
    Multiple opioids and controlled substances
    Multiple opioids & controlled substancesMany entries include QL, MME, and SDS annotations as indicated per line
    ExamplesActiq, hydrocodone combinations, Adderall and other controlled drugs show QL/MME annotations
    ImplicationThese utilization controls may trigger PA or denial if limits are exceeded
    Multiple opioids and other listed drugs
    Multiple opioids and other drugsSeveral listed drugs include QL and SDS where specified in their formulary rows
    ImplicationSupply limits and quantity limits are enforced at claim adjudication
    ReferenceSee each drug's REQUIREMENTS/LIMITS column for applicable controls
    sildenafil citrate (25/50/100 mg)
    Sildenafil citrate (25/50/100 mg)Annotated with QL in formulary list
    ImplicationMonthly quantity limits apply to these dosage strengths as indicated
    ReferenceSee drug row REQUIREMENTS/LIMITS for specifics
    warfarin
    WarfarinAnnotated with AL (Age Limit) in formulary list
    ImplicationAge-based restrictions may apply to coverage of warfarin formulations
    Provider actionVerify patient age against AL annotation before dispensing
    Filsuvez Gel 10%
    Filsuvez Gel 10%Quantity Limits apply (PA and/or QL noted in drug row)
    ImplicationQL annotations restrict amounts covered and may require PA for larger supplies
    ReferenceSee REQUIREMENTS/LIMITS column for this product
    Litfulo
    Litfulo (Opzelura Cream)Annotated with PA and QL in formulary list
    ImplicationPrior authorization and quantity limits apply to Litfulo as noted
    ReferenceSee REQUIREMENTS/LIMITS column for details
    Prudoxin cream 5%
    Prudoxin cream 5%Quantity Limits (QL) and AL annotations present in formulary list
    ImplicationCoverage may be limited by quantity and age restrictions
    ReferenceSee REQUIREMENTS/LIMITS column for Prudoxin cream
    Dexcom sensors
    Dexcom sensorsDexcom Continuous Glucose Monitor sensors are annotated with PA and QL (quantity limits apply)
    ImplicationClaims for Dexcom sensors require prior authorization and are subject to quantity limits
    ReferenceSee drug rows for Dexcom G7/G6/G5/G4 sensors in formulary list
    Insulin and diabetes supplies (Apidra; Basaglar; Bydureon; Fiasp)
    Insulin and diabetes supplies (examples)Certain insulin products (Apidra, Basaglar, Bydureon, Fiasp) and diabetes supplies are annotated with QL
    ImplicationQuantity limits apply to many insulin formulations and diabetes supplies; PA may also be required for some
    ReferenceSee REQUIREMENTS/LIMITS columns in formulary listing for specifics
    Eversense E3 Sensor
    Eversense E3 SensorAnnotated with PA and QL in formulary list
    ImplicationPrior authorization and quantity limits apply to Eversense sensors
    ReferenceSee REQUIREMENTS/LIMITS column for Eversense E3 Sensor
    Insulin products (various)
    Insulin products (various)Multiple insulin products are annotated with QL in the formulary list
    ImplicationQuantity limits apply monthly for many insulin formulations
    ReferenceSee individual insulin product rows for exact QL and PA annotations
    Teriparatide Pen‑Injector
    Teriparatide Pen‑InjectorAnnotated with QIT and QL (quantity over time and quantity limits)
    ImplicationClaims subject to QIT/QL and may require prior authorization as indicated
    ReferenceSee formulary row for Teriparatide Pen‑Injector 620mcg/2.48ml and related strengths
    Multiple listed drugs — QL/QIT annotations
    Multiple listed drugsVarious drugs in the formulary are annotated with QL or QIT where noted per drug row
    ImplicationProviders should reference individual drug rows for applicable quantity/time limits
    ActionExceeding QL/QIT may require PA or supporting documentation
    Adalimu-Adaz Inj 40/0.4ml (Sandoz)
    Adalimu-Adaz Inj 40/0.4ml (Sandoz)Annotated with QL in formulary list
    ImplicationQuantity limits apply to this adalimumab biosimilar product as shown in drug row
    ReferenceSee REQUIREMENTS/LIMITS column for details
    Adalimumab-adbm Prefilled Syringe Kit
    Adalimumab-adbm Prefilled Syringe KitAnnotated with QL (and PA in some entries) in formulary list
    ImplicationQuantity limits and prior authorization may apply to this adalimumab product
    ReferenceSee drug row REQUIREMENTS/LIMITS for specifics